Company research
Solid Biosciences Inc.
CIK 1707502Updated Sep 24, 2026
SecuritySLDB · NASDAQ · equity
Name history
Solid Biosciences, LLC · through Jan 25, 2018
SLDB price & chart
Loading TradingView…
NASDAQ:SLDB on TradingView ↗About the company
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
In the news
Solid Biosciences to Participate at Upcoming Investor Conferences ↗
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm News provided by Kaskela Law LLC Jul 10, 2025, 08:00 ET Share this article Share to X Share this article Share to X PHILADELPHI ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 232,540,000Source | 188,662,000Source | 164,939,000Source | 260,252,000Source |
| Property, Plant and Equipment, NetUSD | 4,169,000Source | 4,747,000Source | 6,624,000Source | 9,657,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 59,900,000Source | 80,235,000Source | 74,015,000Source | 155,384,000Source |
| Assets, CurrentUSD | 205,456,000Source | 157,302,000Source | 129,734,000Source | 219,638,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 16,384,000Source | 8,382,000Source | 6,094,000Source | 5,916,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,924,000Source | 24,295,000Source | 26,539,000Source | 28,949,000Source |
| Other Assets, NoncurrentUSD | 223,000Source | 366,000Source | 209,000Source | 175,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 52,530,000Source | 51,416,000Source | 38,458,000Source | 48,586,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 79,000Source | 40,000Source | 20,000Source | 20,000Source |
| Retained Earnings (Accumulated Deficit)USD | -957,775,000Source | -783,450,000Source | -658,753,000Source | -562,738,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 52,000Source | 47,000Source | 15,000Source | -68,000Source |
| Stockholders' Equity Attributable to ParentUSD | 180,010,000Source | 137,246,000Source | 126,481,000Source | 211,666,000Source |
| Additional Paid in Capital, Common StockUSD | 1,137,654,000Source | 920,609,000Source | 785,199,000Source | 774,452,000Source |
| Liabilities and EquityUSD | 232,540,000Source | 188,662,000Source | 164,939,000Source | 260,252,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 33,472,000Source | 30,257,000Source | 14,517,000Source | 22,508,000Source |
| Operating Lease, Liability, CurrentUSD | 2,103,000Source | 1,787,000Source | 1,855,000Source | 1,897,000Source |
| Accounts Payable, CurrentUSD | 3,224,000Source | 4,237,000Source | 2,032,000Source | 3,238,000Source |
| Operating Lease, Liability, NoncurrentUSD | 19,058,000Source | 21,159,000Source | 22,707,000Source | 24,279,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 96,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 18,945,000Source | 19,852,000Source | 10,137,000Source | 16,691,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 187,900,000Source | 148,900,000Source | 123,640,000Source | 213,722,000Source |
| Deferred Tax Liabilities, NetUSD | 5,307,000Source | 5,914,000Source | 7,299,000Source | 7,934,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -174,325,000Source | -124,697,000Source | -96,015,000Source | -85,981,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 16,914,000Source | 10,519,000Source | 7,625,000Source | 7,537,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,093,000Source | 2,205,000Source | -764,000Source | -5,246,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -156,289,000Source | -100,012,000Source | -94,180,000Source | -97,977,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -58,454,000Source | -16,086,000Source | 9,689,000Source | 59,157,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,153,000Source | 654,000Source | 1,515,000Source | 3,015,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 194,446,000Source | 122,437,000Source | 3,122,000Source | 74,831,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -20,297,000Source | 6,339,000Source | -81,369,000Source | 36,011,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 61,890,000Source | 82,187,000Source | 75,848,000Source | 157,217,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 16,914,000Source | 10,519,000Source | 7,625,000Source | 7,537,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 187,900,000Source | 148,900,000Source | 123,640,000Source | 213,722,000Source |
| DepreciationUSD | — | — | 2,581,000Source | 2,408,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | -6,050,000Source | -4,750,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -374,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 249,000Source |
| General and Administrative ExpenseUSD | 38,881,000Source | 33,297,000Source | 27,752,000Source | 28,948,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | -203,000Source | 340,000Source | — | — |
| Investment Income, InterestUSD | 9,904,000Source | 9,469,000Source | 7,142,000Source | 2,616,000Source |
| Nonoperating Income (Expense)USD | 4,881,000Source | 5,031,000Source | 8,237,000Source | 20,471,000Source |
| Operating ExpensesUSD | 179,206,000Source | 129,728,000Source | 104,252,000Source | 114,546,000Source |
| Other Nonoperating Income (Expense)USD | 824,000Source | 652,000Source | 1,095,000Source | -381,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 2,974,000Source | 72,551,000Source |
| Proceeds from Stock Options ExercisedUSD | 6,000Source | 457,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 8,094,000Source |
| Operating Income (Loss)USD | -179,206,000Source | -129,728,000Source | -104,252,000Source | -106,452,000Source |
| Other Nonoperating Income (Expense)USD | 824,000Source | 652,000Source | 1,095,000Source | -381,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -174,199,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Earnings Per Share, BasicUSD per share | -1.99Source | -3.06Source | -4.83Source | -10.1Source |
| Earnings Per Share, DilutedUSD per share | -1.99Source | -3.06Source | -4.83Source | -10.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 87,504,631Source | 40,816,694Source | 19,884,007Source | 8,512,089Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 87,504,631Source | 40,816,694Source | 19,884,007Source | 8,512,089Source |
| Interest Expense (non-operating)USD | -203,000Source | 340,000Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,636,000Source | 2,455,000Source | 2,581,000Source | 2,408,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | -6,050,000Source | -4,750,000Source | — | — |
| General and Administrative ExpenseUSD | 38,881,000Source | 33,297,000Source | 27,752,000Source | 28,948,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -174,199,000Source | — | — | — |
| Investment Income, InterestUSD | 9,904,000Source | 9,469,000Source | 7,142,000Source | 2,616,000Source |
| Nonoperating Income (Expense)USD | 4,881,000Source | 5,031,000Source | 8,237,000Source | 20,471,000Source |
| Operating ExpensesUSD | 179,206,000Source | 129,728,000Source | 104,252,000Source | 114,546,000Source |
| Research and Development ExpenseUSD | 140,325,000Source | 96,431,000Source | 76,563,000Source | 78,420,000Source |
Filing attachments
d81855dex41.htm · 8-K · 2026-03-06
EX-4.1 2 d81855dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (I…
Read attachment ↗d87050dex991.htm · 8-K · 2025-11-03
EX-99.1 2 d87050dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with the FDA to discuss potential registrational pathways in H1 2026 - - SGT-00…
Read attachment ↗d87050dex992.htm · 8-K · 2025-11-03
EX-99.2 3 d87050dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 [Graphic Appears Here] November 2 0 2 5 Corporate Presentation 87050-004-Part-503Nov25 13:39Page 22[Graphic Appears Here] Cautionary Note Regarding Forward Looking Statements statements This presentation regarding contains future “forward expectations, -looking plans statements” and prospects within the for the meaning company; of the the Private ability Securities to successfully Litigation achieve Reform and Act execute of 1995, on…
Read attachment ↗d908068dex41.htm · 8-K · 2025-02-18
EX-4.1 3 d908068dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SOLID BIOSCIENCES INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: February [ ], 2025 ──────────────────────────────────────────────────────────── Solid Biosciences Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or…
Read attachment ↗d908068dex991.htm · 8-K · 2025-02-18
EX-99.1 5 d908068dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Solid Biosciences Announces Pricing of Underwritten Offering CHARLESTOWN, Massachusetts, February 18, 2025 - Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of commo…
Read attachment ↗d913726dex991.htm · 8-K · 2025-02-18
EX-99.1 2 d913726dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 February 2025 SGT-003 INSPIRE DUCHENNE DATA UPDATE © 2025 Solid Biosciences Cautionary Note Regarding Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the Company; the ability to successfully achieve and execute on the Company’s goals, priorities and …
Read attachment ↗